Takeda Reports Results of Ninlaro (ixazomib) in a P-III Clinical Study for Newly Diagnosed Multiple Myeloma

 Takeda Reports Results of Ninlaro (ixazomib) in a P-III Clinical Study for Newly Diagnosed Multiple Myeloma

Takeda Reports Results of Ninlaro (ixazomib) in a P-III Clinical Study for Newly Diagnosed Multiple Myeloma

Shots:

  • The P-III TOURMALINE-MM2 involves assessing of Ninlaro (ixazomib) + lenalidomide and dexamethasone vs PBO + lenalidomide and dexamethasone in 705 adult patients with newly diagnosed MM patients not eligible for autologous stem cell transplant
  • Results: 13.5mos. increase in m-PFS (35.3 vs 21.8mos.); trial did not meet the threshold for statistical significance and 1Eps of PFS. In the prespecified expanded high-risk cytogenetics subgroup, m-PFS (23.8 vs 18.0mos.); rate of CR (26% vs 14%); m-TTP (45.8 vs 26.8mos.); m-OS not reached @ median follow up of (57.8 vs 58.6mos.)
  • Ninlaro (ixazomib) is an oral proteasome inhibitor, being studies across the continuum of multiple myeloma treatment settings

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Gulf daily News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post